ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "corticosteroids"

  • Abstract Number: 1461 • ACR Convergence 2021

    Belimumab Improves Renal Responses in Patients with or Without Steroid Pulses During Induction Therapy for Lupus Nephritis

    Richard Furie1, Frédéric Houssiau2, Liz Lightstone3, Xueqing Yu4, Julia Weinmann-Menke5, Yoshiya Tanaka6, Angela Jones-Leone7, Tania Gonzalez-Rivera7, Jennifer Gilbride8, Anuradha Madan7, Yulia Green8 and David Roth7, 1Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, 2Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium, 3Department of Immunology and Inflammation, Imperial College, London, United Kingdom, 4Guangdong Provincial People’s Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China (People's Republic), 5University Hospital Mainz, Mainz, Germany, 6University of Occupational and Environmental Health, Kitakyushu, Japan, 7GlaxoSmithKline, Collegeville, PA, 8GlaxoSmithKline, Brentford, United Kingdom

    Background/Purpose: In the BLISS-LN trial (GSK Study BEL114054; NCT01639339), the administration of belimumab (BEL), a B-lymphocyte stimulator antagonist, resulted in improved renal outcomes in patients…
  • Abstract Number: 1642 • ACR Convergence 2021

    Baseline Body-mass-index and Risk for Obesity in Children with Rheumatic Disease on Moderate to High-dose Prednisone Therapy

    Roberta Berard1, Michael Rieder2, Erkan Demirkaya2, Michael Miller3 and Renee Pang2, 1London Health Sciences Centre, London, ON, Canada, 2University of Western Ontario, London, ON, Canada, 3University of Western Ontario, Children's Research Institute, London, ON, Canada

    Background/Purpose: Prednisone is a glucocorticoid (GC) medication commonly used in moderate ( >7.5 mg per day) to high doses (≥ 1 mg/kg/day) for children with…
  • Abstract Number: 1678 • ACR Convergence 2021

    Favorable Balance of Benefit and Harm of Long-Term, Low Dose Prednisolone Added to Standard Treatment in Rheumatoid Arthritis Patients Aged 65+: The Pragmatic, Multicenter, Placebo-Controlled GLORIA Trial

    Maarten Boers1, Linda Hartman1, Daniela Opris-Belinski2, Reinhard Bos3, Marc Kok4, Jose Pereira da Silva5, Ed Griep6, Ruth Klaasen7, Cornelia F. Allaart8, Paul Baudoin9, Hennie Raterman10, Zoltan Szekanecz11, Frank Buttgereit12, Pavol Masaryk13, L. Thomas Klausch1, Sabrina Paolino14, Annemarie Schilder3, Willem Lems15 and Maurizio Cutolo14, 1Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, 2Carol Davila University, Bucharest, Romania, 3Medical Center Leeuwarden, Leeuwarden, Netherlands, 4Maasstad Hospital, Rotterdam, Netherlands, 5University of Coimbra | UC · Clínica Universitária de Reumatologia. Faculty of Medicine, Columbia, Portugal, 6Antonius Hospital, Sneek, Netherlands, 7Meander Medical Center, Amersfoort, Netherlands, 8Leiden University Medical Center, Leiden, Netherlands, 9Reumazorg Flevoland, Emmeloord, Netherlands, 10Northwest Clinics, Alkmaar, Netherlands, 11Division of Rheumatology, University of Debrecen, Faculty of Medicine, Debrecen, Hungary, 12Charité – Universitätsmedizin Berlin, Berlin, Germany, 13National Institute for the Rheumatic Diseases, Bratislava, Slovakia, 14Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Polyclinic San Martino Hospital, Genoa, Italy, 15VUmc, Amsterdam, Netherlands

    Background/Purpose: Low-dose glucocorticoid (GC) therapy is widely used in rheumatoid arthritis (RA) but the balance of benefit and harm is still unclear. We studied the…
  • Abstract Number: 1735 • ACR Convergence 2021

    Glucocorticoid Discontinuation in Patients with Systemic Lupus Erythematosus with Prior Severe Organ Manifestation

    Takehiro Nakai1, Futoshi Iwata1, Genki Kidoguchi1, Sho Fukui2, Hiroki Ozawa1, Satoshi Kawaai3, Yukihiko Ikeda1, Ayako Koido4, Masei Suda5, Atsushi Nomura6, Hiromichi Tamaki1, Kenichi YAMAGUCHI1 and Masato Okada1, 1St. Luke's International Hospital, Tokyo, Japan, 2Immuno-Rheumatology Center, St. Luke’s International Hospital, and Center for clinical epidemiology, St. Luke’s International University, Tokyo, Japan, 3Immuno-Rheumatology Center, St. Luke’s International Hospital, Tokyo, Japan, Chuo-ku, Tokyo, Japan, 4St. Luke's International Hospital, Akashi-cho, Chuo-ku, Tokyo, Japan, 5Suwa Central Hospital, Nagano, Japan, 6St. Luke's International Hospital, Nagareyama, Japan

    Background/Purpose: Most long-term damage in systemic lupus erythematosus (SLE) has been attributed to continuous glucocorticoid use; however, glucocorticoid discontinuation is occasionally associated with disease flare-ups.…
  • Abstract Number: 1914 • ACR Convergence 2021

    Immunomodulatory and Immunosuppressive Medication Modification Among Rheumatology Patients at the Time of COVID-19 Vaccination

    Jonah Levine1, Deanna Jannat-Khah1, Vivian Bykerk2, Lisa Mandl1 and Medha Barbhaiya1, 1Hospital for Special Surgery, New York, NY, 2Division of Rheumatology, Hospital for Special Surgery, New York City, NY

    Background/Purpose: Due to concerns about underlying immune dysregulation and immunosuppression, patients with systemic rheumatic diseases (SRD) may have modified their medications at the time of…
  • Abstract Number: 1679 • ACR Convergence 2020

    Developing a Standardized Corticosteroid Dosing Regimen in Pediatric Proliferative Lupus Nephritis

    Nathalie Chalhoub1, Kelly Rouster-Stevens2, Marisa Klein-Gitelman3, Karen Onel4, Beatrice Goilav5, Sonia Savani6, Natasha Ruth6, Tingting Qiu7, Najla Aljaberi8, Jianghong Deng9, Angela Merritt8, Benjamin Laskin10, Anna Carmela Sagcal-Gironella11, Stacy Ardoin12, Deborah Levy13, Scott Wenderfer14, Bin Huang7, Hermine I Brunner15 and LaUNCH Project Investigators16, 1The University of Cincinnati College of Medicine, Cincinnati, OH, 2Emory University/Children's Healthcare of Atlanta, Atlanta, GA, 3Division of Rheumatology, Department of Pediatrics, Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, 4Pediatric Rheumatology, Hospital for Special Surgery, New York, NY, 5The Children’s Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, NY, 6Medical University of South Carolina, Charleston, SC, 7Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 8Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 9Beijing Children’s Hospital, Beijing, China (People's Republic), 10Children's Hospital of Philadelphia, Philadelphia, 11Hackensack Meridian School of Medicine at Seton Hall University, Hackensack, NJ, 12Nationwide Children's Hospital, Columbus, OH, 13Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, 14Renal Section, Baylor College of Medicine and Texas Children's Hospital, Houston, TX, 15PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 16LUpus Nephritis and Cellcept precision dosing in cHildren (LaUNCH), Cincinnati, OH

    Background/Purpose: Corticosteroids (CS) remain the mainstay of therapy for childhood-onset systemic lupus erythematosus (cSLE). However, widely accepted strategies for oral (PO) or intravenous (IV) CS…
  • Abstract Number: 1687 • ACR Convergence 2020

    Kawasaki Disease Shock Syndrome in the Intensive Care Unit: A Single Center Cohort

    Monica Bray1, Jennifer Rammel2, Andrea Ramirez1, Kristen Sexson1, Fong Lam1, Eyal Muscal3 and Marietta DeGuzman3, 1Baylor College of Medicine, Houston, TX, 2University of Florida Health Jacksonville, Jacksonville, FL, 3Baylor College of Medicine, Houston

    Background/Purpose: Kawasaki disease (KD), a well described vasculitis of childhood, is the leading cause of acquired heart disease in developed countries. Kawasaki disease shock syndrome…
  • Abstract Number: 1948 • ACR Convergence 2020

    Identification of Small Molecules with Efficacy as Steroid Sparing Suppression of Chemokine and Cytokine Production by Rheumatoid Arthritis Fibroblast-like Synoviocytes

    Tadashi Hosoya1, Nikunj Shukla2, Yuya Fujita3, Shiyin Yao4, Fitzgerald Lao4, Hiroyuki Baba1, Shinsuke Yasuda5, Howard Cottam4, Dennis Carson4, Tomoko Hayashi4 and Mary Corr6, 1Department of Rheumatology, Tokyo Medical and Dental University (TMDU), Tokyo, Tokyo, Japan, 2Moores Cancer Center, University of California San Diego, San Diego, CA, 3Department of Medicine, University of California San Diego, San Diego, CA, 4Moores Cancer Center, University of California San Diego, San Diego, 5Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Tokyo, Japan, 6Department of Medicine, University of California San Diego, San Diego

    Background/Purpose: Target-based drug discovery has expanded our therapeutic armamentarium in the treatment of inflammatory and autoimmune diseases. Despite these advances, glucocorticoids (GC) remain reliable agents…
  • Abstract Number: 0111 • ACR Convergence 2020

    Assessment and Treatment of Glucocorticoid-Induced Osteoporosis in a Rheumatology Clinic

    Amanda Stefl1, Shikha Singla2, Jessica Michaud1, Kama Thomas2, Lisa Rein2 and Mary Ellen Csuka2, 1Froedtert Hospital, Milwaukee, WI, 2Medical College of Wisconsin, Milwaukee, WI

    Background/Purpose: Glucocorticoids (GC) are used as a long-term treatment option for an estimated 1% of the US population. The American College of Rheumatology has maintained…
  • Abstract Number: 0113 • ACR Convergence 2020

    Improving Glucocorticoid-Induced Osteoporosis Screening and Management in Patients with Rheumatic Diseases Using the 2017 ACR Guidelines

    Marielys Figueroa Sierra1, Atefeh Vafa1, Shu Cao2, Yuanyuan Lu3, Helen Bateman4, John Carter1, Yih Chang Lin2, Raquel Cuchacovich1, Marcos Maldonado4, Joanne Valeriano-Marcet1 and Gabriela Montes-Rivera4, 1University of South Florida, Tampa, FL, 2University of South Florida, Morsani College of Medicine, Tampa, FL, 3Biostatistician at Graduate Medical Education Department, Tampa, FL, 4James A. Haley VA, Tampa, FL

    Background/Purpose: Glucocorticoid-induced osteoporosis (GIOP) is a potentially preventable complication in those who are maintained on glucocorticoid (GC) therapy.  It is imperative to identify these patients…
  • Abstract Number: 0404 • ACR Convergence 2020

    Isolated Aortitis: Single Centre Experience of Clinical Spectrum and Management

    Nadia Ahmad1, Ayna Verdiyeva2, Raashid Luqmani2 and Shirish Dubey2, 1Oxford University Hospitals NHS Foundation Trust, Reading, United Kingdom, 2Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom

    Background/Purpose: Aortitis was previously regarded as a rare form of large vessel vasculitis (LVV), but is now increasingly being recognised. It may occur in the…
  • Abstract Number: 0466 • ACR Convergence 2020

    Dosage Modification of Immunomodulatory Medications by Rheumatology Patients in New York City During the Peak of the COVID-19 Pandemic

    Marianna Frey1, Gregory Vitone2, Candace Feldman3, Lindsay Lally1, Anne Bass4, Jane Salmon1, Mary Crow1, Michael Lockshin5, Vivian Bykerk1, Lisa Mandl1 and Medha Barbhaiya5, 1Hospital for Special Surgery, New York, NY, 2Hospital for Special Surgery, New York, 3Brigham and Women's Hospital, Boston, 4Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, 5Hospital for Special Surgery, Barbara Volcker Center for Women and Rheumatic Diseases, New York, NY

    Background/Purpose: Due to concerns about underlying immune dysregulation and immunosuppression, patients with systemic rheumatic diseases living in COVID-19 “hot spots” may have modified their immunomodulatory…
  • Abstract Number: 0872 • ACR Convergence 2020

    Usage of Corticosteroids and Hospitalisation Duration in Adult Patients with Systemic Lupus Erythematosus (SLE) in Latvia

    Ilze Vinkalna1, Inita Bulina2, Natalija Vellere2, Kristine Ivanova2, Pauls Rubins2, Renate Diura2, Santa Mikena2, Julija Zepa2 and Daina Andersone2, 1Pauls Stradins Clinical University Hospital, Rīga, Latvia, 2Pauls Stradins Clinical University Hospital, Riga

    Background/Purpose: To determine the factors influencing hospitalisation duration, re – hospitalisation (more than 1 hospitalisation during the study period), frequency of the usage of corticosteroids…
  • Abstract Number: 1014 • ACR Convergence 2020

    Disease Modifying Anti-rheumatic Drugs, Biologics and Corticosteroid Use in Older Patients with Rheumatoid Arthritis over 20 Years

    John Hanly1 and Lynn Lethbridge2, 1Dalhousie University, Halifax, NS, Canada, 2Dalhousie University, Halifax, Canada

    Background/Purpose: The objective of the current study was to examine the change in prescribing patterns for older adults with RA over a 20 year period…
  • Abstract Number: 1569 • ACR Convergence 2020

    Immune Related Adverse Events Related to Check Point Inhibitors Among Outpatients in an Academic Center

    Bushra Akram1, Aleena Itani1, Mohammad Razaq2, Samera Vaseer1, Sara Vesely1 and Pawan Acharya1, 1University of Oklahoma Health Sciences Center, Oklahoma City, 2University of Oklahoma Health Sciences Center, Oklahoma City, OK

    Background/Purpose: Immune check point inhibitors (ICIs) allow the body to recognize tumor cells as non-self, resulting in immune-cell mediated tumor cell destruction. These therapies have the…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 12
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology